| Delaware (State or other jurisdiction of incorporation or organization) | | | 22-3627252 (I.R.S. Employer Identification No.) | |
| Large accelerated filer ☐ | | | | | | Accelerated filer ☐ | |
| Non-accelerated filer ☐ | | | | | | Smaller reporting company ☒ | |
| | | | | | | Emerging growth company ☐ | |
| | | Page | | |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 7 | | | |
| | | | 9 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 14 | | |
| Securities and Exchange Commission registration fee | | | | $ | 11,665.68(1) | | |
| FINRA fee (if applicable) | | | | | * | | |
| Printing expenses | | | | | * | | |
| Legal fees and expenses | | | | | * | | |
| Accounting fees and expenses | | | | | * | | |
| Transfer agent and trustee fees and expenses | | | | | * | | |
| Miscellaneous | | | | | * | | |
| Total | | | | $ | * | | |
Exhibit No. | | | Description of Exhibit | |
4.26* | | | Form of Warrant | |
4.27* | | | Form of Warrant Agreement for Common Stock, including Warrant Certificate for Common Stock | |
4.28* | | | Form of Warrant Agreement for Preferred Stock, including Warrant Certificate for Preferred Stock | |
4.29* | | | Form of Warrant Agreement for Debt Securities, including Warrant Certificate for Debt Securities | |
4.30* | | | Form of Unit Agreement | |
5.1*** | | | | |
23.1*** | | | | |
23.3*** | | | Consent of Morgan, Lewis & Bockius LLP (included in the opinion filed as Exhibit 5.1) | |
24.1*** | | | Power of attorney (included on the signature page of this registration statement) | |
25.1** | | | Form T-1 Statement of Eligibility and Qualification under the Trust Indenture Act of 1939 of Trustee for Form of Indenture. | |
107 | | | |
| Name | | | Title | | | Date | |
| /s/ Steven M. Fruchtman, M.D. Steven M. Fruchtman, M.D. | | | Director, President and Chief Executive Officer (Principal Executive Officer) | | | June 30, 2023 | |
| /s/ Mark Guerin Mark Guerin | | | Chief Operating Officer and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | | | June 30, 2023 | |
| /s/ James J. Marino James J. Marino | | | Chairman, Board of Directors | | | June 30, 2023 | |
| /s/ Peter Atadja, Ph.D. Peter Atadja, Ph.D. | | | Director | | | June 30, 2023 | |
| /s/ Trafford Clarke, Ph.D. Trafford Clarke, Ph.D. | | | Director | | | June 30, 2023 | |
| /s/ Jerome E. Groopman, M.D. Jerome E. Groopman, M.D. | | | Director | | | June 30, 2023 | |
| /s/ Viren Mehta, Pharm.D. Viren Mehta, Pharm.D. | | | Director | | | June 30, 2023 | |
| Name | | | Title | | | Date | |
| /s/ M. Teresa Shoemaker M. Teresa Shoemaker | | | Director | | | June 30, 2023 | |
| /s/ Jack E. Stover Jack E. Stover | | | Director | | | June 30, 2023 | |